CareLit Fachartikel

Analysis of mutations in the BCR-ABL TK domain in CML patients

M Neßlboeck, S Preuner, T Lion · Klinische Pädiatrie · 2010 · Heft 05

Dokument
1169227
CareLit-ID
Jahr
2010
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Klinische Pädiatrie
Autor:innen
M Neßlboeck, S Preuner, T Lion
Ausgabe
Heft 05 / 2010
Seiten
–
Erschienen: 2010-05-07 00:00:00
ISSN
0300-8630
DOI
10.1055/s-0030-1254459

Zusammenfassung

Background: The tyrosine kinase (TK) inhibitor imatinib (Gleevec®) directed against the BCR-ABL TK domain has become the standard of treatment in patients with chronic myeloid leukemia (CML). Despite its effectiveness in CML treatment, primary refractory disease or secondary resistance remains a problem. The mechanisms underlying resistance is most commonly associated with point mutations within the ABL TK domain. Methods: A number of methods have been employed to detect mutant clones in the BCR-ABL TK domain. PCR amplification coupled with direct bidirectional sequencing is relatively rapid and allows detection…

Schlagworte

Mutations Domain Patients Bcr-Abl Treatment Resistance Detection Imatinib Within Methods Mutant Clones Klinische Pädiatrie